ATR – aptargroup, inc. (US:NASDAQ)
New Study Using Aptar's Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer's Drug Directly to the Brain [Yahoo! Finance]
New Study Using Aptar’s Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer’s Drug Directly to the Brain
AptarGroup, Inc. (NYSE: ATR) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $173.00. They now have an "overweight" rating on the stock.
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
AptarGroup, Inc. (NYSE: ATR) had its price target raised by analysts at Raymond James Financial, Inc. from $175.00 to $182.00. They now have an "outperform" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com